Replies to post #181804 on Biotech Values

[DewDiligence]

JNJ acquires Alios (private) for $1.75B in cash:

http://finance.yahoo.com/news/johnson-johnson-announces-agreement-acquire-123000575.html

Alios has an RSV drug (AL-8176) in phase-2 and an HCV nuke in preclinical development, as noted in #msg-106165891. JNJ’s PR doesn’t mention the HCV nuke, but it's reasonable to surmise that the HCV nuke influenced the deal value to a non-trivial degree.